drugset / Trial / NCT02183051

Study to Compare the the Analgesic Efficacy and Tolerability of Meloxicam Versus Placebo and Ibuprofen in the Treatment of Pain After Surgery of the Third Molar

NCT02183051

Phase 2 Completed 381 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

To assess the analgesic efficacy and tolerability of meloxicam 15 mg, 7.5 mg, 3.75 mg and 1.875 mg oral (rapid release tablet) compared with placebo and ibuprofen 400 mg and 200 mg administered in a single dose, over an observation period of 6 hours in the treatment of pain after surgery of the third molar.

Timeline

Start
1998-04
Primary completion
1998-10
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ibuprofen Small molecule 200 mg Oral
Comparator Ibuprofen Small molecule 400 mg Oral
Subject Meloxicam Small molecule 1.875 mg Oral
Subject Meloxicam Small molecule 3.75 mg Oral
Subject Meloxicam Small molecule 7.5 mg Oral
Subject Meloxicam Small molecule 15 mg Oral

Indications

No indication recorded.